PLEC and astrocytoma (excluding glioblastoma): For validating plectin’s potential as a biomarker of GBMs, it will be essential to investigate its re-localization within the cytoplasm, assess its surface expression, and measure the direct release of plectin in biopsy specimens obtained from GBMs and lower-grade astrocytomas.